20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
NECTAR 2021
This event brought together scientists, clinicians, patient advocates and industry partners from across Europe and the international community to share the latest research in repairing the damage to the central nervous system as a result of degenerative diseases. Our Deputy Director of Research, Dr Simon…
The clinical trials pipeline for Parkinson’s: 2020/21
Despite the difficulties throughout 2020, a significant amount of clinical trial activity for Parkinson’s was conducted and a new report – involving the research team at Cure Parkinson’s – highlights the landscape of therapeutics being developed for Parkinson’s.
Farnesol: The farnesylator of PARIS
A build up of “PARkin Interacting Substrate” (or PARIS) protein has been proposed as one potential mediator of the pathology observed in some cases of Parkinson’s. The accumulation of this protein leads to the inhibition of a key protein called PGC-1α, which is a neuroprotective protein that helps to keep cells […]
The Henley Mermaids take on the Bristol Channel
On 20 July, Laura Reineke, Jo Robb, Fiona Print, Susan Barry and Joan Fennelly, otherwise known as the Henley Mermaids, swam 61km across the Bristol Channel in support of Cure Parkinson’s and three other charities dedicated to neurological conditions. The Henley Mermaids are a group…
The Bluerockers have started
On the 8th June, BlueRock Therapeutics put out a press release announcing that the first participant in their Phase I clinical trial of cell transplantation for Parkinson’s had been dosed (Click here to read the press release). The initiation of this clinical trial by the company is a major step forward […]